Prognostic Significance of Occult Bone Marrow Micrometastases of Breast Cancer Detected by Quantitative Polymerase Chain Reaction for Cytokeratin 19 mRNA

Amplification of cytokeratin 19 (CK19) transcripts by reverse transcriptase‐polymerase chain reaction (RT‐PCR) has been shown to be a highly sensitive assay for the detection of bone marrow micrometastases (BMM) of breast cancer, but recent studies have demonstrated the occurrence of false‐positive results due to low‐level, illegitimately transcribed CK19 in normal bone marrow tissue. One approach to solve this problem is to develop a quantitative CK19 RT‐PCR assay and to introduce a cut‐off value which can distinguish between illegitimate expression and cancer‐specific expression levels. In the present paper, we describe a quantitative CK19 RT‐PCR assay using a real‐time automated PCR system. The number of CK19 transcripts was normalized to that of GAPDH transcripts as an internal control for quality and quantity of cDNA. The cut‐off value for the ratio of CK19 to GAPDH transcripts was set at 10−4 since the ratio never exceeded this value in the control bone marrow samples (n=12). In total, 117 bone marrow aspirates from stage I‐III patients with invasive breast cancers were subjected to CK19 RT‐PCR assay and immunocytological examination. Forty (34.2%) were found to be BMM‐positive by CK19 RT‐PCR assay whereas only three (2.6%) were found to be BMM‐positive by immunocytology. Multivariate analysis has shown that occult BMM detected by CK19 RT‐PCR is a significant risk factor for relapse, being independent of axillary lymph node metastases.

[1]  R. Coombes,et al.  Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study , 1999, The Lancet.

[2]  R C Coombes,et al.  Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Hovig,et al.  Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase‐polymerase chain reaction assays used to detect micrometastatic tumor cells , 1999, International journal of cancer.

[4]  A. Giuliano,et al.  Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Funke,et al.  Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[7]  B. Garicochea,et al.  Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. , 1997, Molecular pathology : MP.

[8]  M. Monden,et al.  Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase‐polymerase chain reaction , 1997, International journal of cancer.

[9]  J. López-Guerrero,et al.  Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). , 1997, Clinica chimica acta; international journal of clinical chemistry.

[10]  R. Coombes,et al.  The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. , 1997, European journal of cancer.

[11]  J. Perkins,et al.  Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[13]  S. Ethier,et al.  Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Eiermann,et al.  Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. , 1994, British Journal of Cancer.

[15]  P. Sismondi,et al.  Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. , 1990, Anticancer research.